Ponatinib promotes a G(1) cell-cycle arrest of merlin/NF2-deficient human schwann cells

Neurofibromatosis type 2 (NF2) is a genetic syndrome that predisposes individuals to multiple benign tumors of the central and peripheral nervous systems, including vestibular schwannomas. Currently, there are no FDA approved drug therapies for NF2. Loss of function of merlin encoded by the NF2 tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrilli, Alejandra M, Garcia, Jeanine, Bott, Marga, Plati, Stephani Klingeman, Dinh, Christine T, Bracho, Olena R, Yan, Denise, Zou, Bing, Mittal, Rahul, Telischi, Fred F, Liu, Xue-Zhong, Chang, Long-Sheng, Bradley, D Welling, Copik, Alicja J, Fernández-Valle, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458238/
https://www.ncbi.nlm.nih.gov/pubmed/28427224
http://dx.doi.org/10.18632/oncotarget.15912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458238/
https://www.ncbi.nlm.nih.gov/pubmed/28427224
http://dx.doi.org/10.18632/oncotarget.15912

Ejemplares similares